DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer

Clinical Epigenetics

Brock C. Christensen⁶  Vessela N. Kristensen¹  Tracy Onega²  Jonathan D. Marotti⁴  Erik G. Jenson⁴  Panpan Chen⁶  Thomas Fleischer³  Devin C. Koestler⁵  Kevin C. Johnson⁶ 

[1] Department of Clinical Molecular Biology (EpiGen), Medical Division, Akershus Hospital, Lørenskog, Norway;The Dartmouth Institute, Geisel School of Medicine at Dartmouth, Lebanon 03766, NH, USA;The K.G. Jebsen Center for Breast Cancer, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway;Department of Pathology, Geisel School of Medicine at Dartmouth, Hanover 03755, NH, USA;Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA;Department of Epidemiology, Geisel School of Medicine at Dartmouth, HB 7650, Remsen 611, Hanover 03755, NH, USA

关键词: TCGA;    Cancer;    DCIS;    Array;    Methylation;    Breast;   

Others  :  1221395
DOI  :  10.1186/s13148-015-0094-0

 received in 2015-03-13, accepted in 2015-06-11,  发布年份 2015

【 摘 要 】

Background

Ductal carcinoma in situ (DCIS) is a heterogeneous, pre-invasive lesion associated with an increased risk for future invasive ductal carcinoma. However, accurate risk stratification for development of invasive disease and appropriate treatment decisions remain clinical challenges. DNA methylation alterations are early events in the progression of cancer and represent emerging molecular markers that may predict invasive recurrence more accurately than traditional measures of DCIS prognosis.

Results

We measured DNA methylation using the Illumina HumanMethylation450K array of estrogen-receptor positive DCIS (n = 40) and adjacent-normal (n = 15) tissues from subjects in the New Hampshire Mammography Network longitudinal breast imaging registry. We identified locus-specific methylation differences between DCIS and matched adjacent-normal tissue (95,609 CpGs, Q < 0.05). Among 40 DCIS cases, 13 later developed invasive disease and we identified 641 CpG sites that exhibited differential DNA methylation (P < 0.01 and median |∆β| > 0.1) in these cases compared with age-matched subjects without invasive disease. The set of differentially methylated CpG loci associated with disease progression was enriched in homeobox-containing genes (P = 1.3E-09) and genes involved with limb morphogenesis (P = 1.0E-05). In an independent cohort, a subset of genes with progression-related differential methylation between DCIS and invasive breast cancer were confirmed. Further, the functional relevance of these genes’ regulation by methylation was demonstrated in early stage breast cancers from The Cancer Genome Atlas database.

Conclusions

This work contributes to the understanding of epigenetic alterations that occur in DCIS and illustrates the potential of DNA methylation as markers of DCIS progression.

【 授权许可】

   
2015 Johnson et al.

【 图 表 】

Fig. 1.

Fig. 2.

Figure 2.

【 参考文献 】

• [1]Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015, 65(1):5-29.
• [2]Warren JL, Weaver DL, Bocklage T, Key CR, Platz CE, Cronin KA, et al.: The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer 2005, 104(9):1840-1848.
• [3]Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al.: Benign breast disease and the risk of breast cancer. N Engl J Med 2005, 353(3):229-237.
• [4]Duggal S, Julian TB: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ. J Natl Cancer Inst 2013, 105(10):681-683.
• [5]van Hoesel AQ, Sato Y, Elashoff DA, Turner RR, Giuliano AE, Shamonki JM, et al.: Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer 2013, 108(10):2033-2038.
• [6]Group EBCC, Group ER, Bijker N, Meijnen P, Peterse JL, Bogaerts J, et al.: Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol Off J Am Soc Clini Oncol 2006, 24(21):3381-3387.
• [7]Wickerham DL, Julian TB: Ductal carcinoma in situ: a rose by any other name. J Natl Cancer Inst 2013, 105(20):1521-1522.
• [8]Marshall E: Breast cancer. Dare to do less Science 2014, 343(6178):1454-1456.
• [9]Pace LE, Keating NL: A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014, 311(13):1327-1335.
• [10]Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, Jovanovic J, et al.: Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast cancer research : BCR 2010, 12(1):R3. BioMed Central Full Text
• [11]Stefansson OA, Esteller M: Epigenetic modifications in breast cancer and their role in personalized medicine. Am J Pathol 2013, 183(4):1052-1063.
• [12]Veeck J, Esteller M: Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010, 15(1):5-17.
• [13]Jones PA: Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13(7):484-492.
• [14]Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al.: Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012, 109(8):2802-2807.
• [15]Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
• [16]Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al.: Breast cancer methylomes establish an epigenomic foundation for metastasis. Science translational medicine 2011, 3(75):75-25.
• [17]Christensen BC, Kelsey KT, Zheng S, Houseman EA, Marsit CJ, Wrensch MR, et al.: Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet 2010., 6(7) Article ID e1001043
• [18]Widschwendter M, Jones PA: DNA methylation and breast carcinogenesis. Oncogene 2002, 21(35):5462-5482.
• [19]Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, et al.: Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 2013, 13:456. BioMed Central Full Text
• [20]Moelans CB, Verschuur-Maes AH, van Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011, 225(2):222-231.
• [21]Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP: Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast cancer research : BCR 2009, 11(1):R14. BioMed Central Full Text
• [22]Pang JM, Dobrovic A, Fox SB: DNA methylation in ductal carcinoma in situ of the breast. Breast cancer research: BCR 2013, 15(3):206. BioMed Central Full Text
• [23]Monti S, Tamayo P, Mesirov J, Golub T: Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 2003, 52(1–2):91-118.
• [24]Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, et al.: Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol 2014, 15(8):435.
• [25]Polyak K: Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010, 2010(41):210-213.
• [26]Aran D, Sabato S, Hellman A: DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol 2013, 14(3):R21. BioMed Central Full Text
• [27]Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, et al.: Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011, 71(19):6195-6207.
• [28]Baylin SB, Ohm JE: Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006, 6(2):107-116.
• [29]Beltran AS, Graves LM, Blancafort P: Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene 2013.
• [30]Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, et al.: HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERalpha and inducing IL-6 expression. Cancer Res 2013, 73(17):5449-5458.
• [31]Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, Shapiro CL, et al.: Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 2008, 29(7):1459-1465.
• [32]Tomida S, Yanagisawa K, Koshikawa K, Yatabe Y, Mitsudomi T, Osada H, et al.: Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene 2007, 26(31):4600-4608.
• [33]Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, et al.: Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2012, 18(10):2896-2904.
• [34]Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
• [35]Wang Y, He X, Ngeow J, Eng C: GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet 2012, 21(3):569-576.
• [36]Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH, et al.: Identification of methylated genes associated with aggressive bladder cancer. PLoS One 2010., 5(8) Article ID e12334
• [37]Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al.: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464(7291):1071-1076.
• [38]Shah N, Sukumar S: The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010, 10(5):361-371.
• [39]MacKenzie TA, Titus-Ernstoff L, Vacek PM, Geller B, Weiss JE, Goodrich ME, et al.: Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer causes & control : CCC 2007, 18(9):939-945.
• [40]Dumenil TD, Wockner LF, Bettington M, McKeone DM, Klein K, Bowdler LM, et al.: Genome-wide DNA methylation analysis of formalin-fixed paraffin embedded colorectal cancer tissue. Genes Chromosomes Cancer 2014, 53(7):537-548.
• [41]Lechner M, Fenton T, West J, Wilson G, Feber A, Henderson S, et al.: Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome med 2013, 5(2):15. BioMed Central Full Text
• [42]S Moran, M Vizoso, A Martinez-Cardus, A Gomez, X Matias-Guiu, SM Chiavenna et al. Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray. Epigenetics: official journal of the DNA Methylation Society. 2014;9(6).
• [43]Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F: Evaluation of the Infinium Methylation 450K technology. Epigenomics 2011, 3(6):771-784.
• [44]Koestler DC, Li J, Baron JA, Tsongalis GJ, Butterly LF, Goodrich M, et al.: Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2014, 27(1):145-155.
• [45]Roessler J, Ammerpohl O, Gutwein J, Hasemeier B, Anwar SL, Kreipe H, et al.: Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina. Inc BMC research notes 2012, 5:210. BioMed Central Full Text
• [46]Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, et al.: ChAMP: 450k Chip Analysis Methylation Pipeline. Bioinformatics 2014, 30(3):428-430.
• [47]Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, et al.: A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 2013, 29(2):189-196.
• [48]Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8(1):118-127.
• [49]Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26(12):1572-1573.
• [50]Jones JL: Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast cancer research : BCR 2006, 8(2):204. BioMed Central Full Text
• [51]Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37(1):1-13.
• [52]Squazzo SL, O’Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, et al.: Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 2006, 16(7):890-900.
• [53]Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al.: Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39(2):232-236.
• [54]Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al.: Control of developmental regulator’s by polycomb in human embryonic stem cells. Cell 2006, 125(2):301-313.
• [55]Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K: Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Gene Dev 2006, 20(9):1123-1136.
• [56]Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al.: The UCSC Table Browser data retrieval tool. Nucleic Acids Res 2004, 32:D493-D496.